Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
| ▸ | MARS1 | P56192 | 13/20 | 0.54 |
| ▸ | GCGR | P47871 | 4/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501855 | 0.86 | MARS1 (0.52) | MAP4K4SRD5A2MARS1GCGR | |
| SCHEMBL11044929 | 0.83 | MAP4K4 (0.55) | MAP4K4PTGS2 | |
| SCHEMBL4725410 | 0.81 | MAP4K4 (0.68) | MAP4K4PTGS2 | |
| SCHEMBL4780143 | 0.80 | EGLN1 (0.56) | MAP4K4GCGRPTGS2 | |
| SCHEMBL3747046 | 0.79 | ALPL (0.52) | SRD5A2MARS1 | |
| SCHEMBL10899210 | 0.78 | AHR (0.52) | SRD5A2MARS1 | |
| SCHEMBL21552113 | 0.77 | EGLN1 (0.58) | MAP4K4GCGRPTGS2 | |
| SCHEMBL5358199 | 0.77 | CNR1 (0.70) | SRD5A2MARS1 | |
| SCHEMBL4463174 | 0.77 | CNR1 (0.64) | SRD5A2MARS1 | |
| SCHEMBL4453192 | 0.77 | CNR1 (0.64) | SRD5A2MARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | claimed |
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | disclosed |
| WO-1984004302-A1 | SUBSTITUTED PICOLINIC ACIDS, PROCESSES FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM | BYK GULDEN LOMBERG CHEM FAB (DE) | 1984-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | MAP4K4 944/4885SRD5A2 671/4885MARS1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.